id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-1792-0002,FDA,FDA-2026-P-1792,Acknowledgement Letter from FDA DMB to PharmaVector LLC,Other,Acknowledgement Letter/Receipt,2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,,2026-02-19T17:45:31Z,,0,0,09000064b91bae37
FDA-2026-P-1792-0005,FDA,FDA-2026-P-1792,"Attachment 3 - Draft Package Insert Proposed for Pregabalin Extended-Release Tablets, 247.5 mg, 495 mg and 660 mg",Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-19T17:46:25Z,,0,0,09000064b91b9245
FDA-2026-P-1792-0001,FDA,FDA-2026-P-1792,Suitability Petition from PharmaVector LLC,Other,Petition(s),2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,,2026-02-19T17:43:47Z,,1,0,09000064b91b9ac5
FDA-2026-P-1792-0003,FDA,FDA-2026-P-1792,Attachment 1 - Copy of the relevant excerpt from the current electronic Edition of Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book),Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-19T17:46:12Z,,0,0,09000064b91b9243
FDA-2026-P-1792-0004,FDA,FDA-2026-P-1792,"Attachment 2 - Current Package Insert for LYRICA CE®, NDA#209501",Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-19T17:46:22Z,,0,0,09000064b91b9244